Abstract:Hematoma volume is the strongest predictor of morbidity and mortality after intracerebral hemorrhage. Protection against early hematoma growth is therefore the mainstay of therapeutic intervention for acute intracerebral hemorrhage, but the current armamentarium is restricted to early blood pressure lowering and emergent reversal for anticoagulant agents. Although intensive lowering of systolic blood pressure to <140 mmHg appears likely to prevent hematoma growth, two recent randomized trials, INTERACT-2 and ATACH-2, demonstrated non-significant trends of reduced hematoma enlargement by intensive blood pressure control, with only a small magnitude of benefit or no benefit for clinical outcomes. While oral anticoagulants can be immediately reversed by prothrombin complex concentrate, or the newly developed idarucizumab for direct thrombin inhibitor or andexanet for factor Xa inhibitors, the situation regarding reversal of antiplatelet agents is not yet quite as advanced. However, considering at most the approximately 10% rate of anticoagulant use among patients with intracerebral hemorrhage, what is most essential for patients with intracerebral hemorrhage in general is early hemostatic therapy. Tranexamic acid may safely reduce hematoma expansion, but its hemostatic effect was insufficient to be translated into improved functional outcomes in the TICH-2 randomized trial with 2,325 participants. In this context, recombinant activated factor VII (rFVIIa) is a candidate to be added to the armory against hematoma enlargement. The FAST, a phase 3 trial that compared doses of 80 and 20 μg/kg rFVIIa with placebo in 841 patients within 4 h after the stroke onset, showed a significant reduction in hematoma growth with rFVIIa treatment, but demonstrated no significant difference in the proportion of patients with severe disability or death. However, a post hoc analysis of the FAST trial suggested a benefit of rFVIIa in a target subgroup of younger patients without extensive bleeding at baseline when treated earlier after stroke onset. The FASTEST trial is now being prepared to determine this potential benefit of rFVIIa, reflecting the pressing need to develop therapeutic strategies against hematoma enlargement, a powerful but modifiable prognostic factor in patients with intracerebral hemorrhage.

[Acute treatment of intracerebral hemorrhage]

[Treatment of intracerebral hemorrhage - An overview]

The acute management of intracerebral hemorrhage: a clinical review

Intracerebral hemorrhage: an update on diagnosis and treatment

Intracerebral haemorrhage — mechanisms, diagnosis and prospects for treatment and prevention

Emergent Management of Intracerebral Hemorrhage

Treatment for intracerebral hemorrhage: Dawn of a new era

Ultra-Early Hemostatic Therapy for Acute Intracerebral Hemorrhage: An Updated Review

Intracerebral Hemorrhage: A Brief Evidence-Based Review of Common Etiologies, Mechanisms of Secondary Injury, and Medical and Surgical Management

Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions

Clinical Strategies Against Early Hematoma Expansion Following Intracerebral Hemorrhage

Advances in Prehospital Management of Intracerebral Hemorrhage

Surgical Management for Primary Intracerebral Hemorrhage

Essential Topics About the Imaging Diagnosis and Treatment of Hemorrhagic Stroke: A Comprehensive Review of the 2022 AHA Guidelines

Neuroimaging of Acute Intracerebral Hemorrhage

Treatment Strategies to Attenuate Perihematomal Edema in Patients With Intracerebral Hemorrhage

Stem Cell Therapy: A Promising Therapeutic Method for Intracerebral Hemorrhage.

Modern Approaches to Evacuating Intracerebral Hemorrhage

Secondary mechanisms of injury and viable pathophysiological targets in intracerebral hemorrhage

Brain edema formation and therapy after intracerebral hemorrhage

Thrombolytic evacuation of intracerebral and intraventricular hemorrhage